The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Almon Einat Brill since 2008.
The trader's CIK number is 1385116.
At the time of the last reporting, Almon Einat Brill was the VP, Product Developm of Protalix Biotherapeutics, Inc.. (stock ticker symbol PLX).
Also see all insider trading activities at Protalix Biotherapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2012 | PLX | 0 | $0 | 166,848 | $1,189,626 | 166,848 | $302,161 |
| 2010 | PLX | 0 | $0 | 120,000 | $1,040,250 | 120,000 | $102,340 |
| 2009 | PLX | 0 | $0 | 185,000 | $1,286,802 | 198,483 | $79,193 |
| 2008 | PLX | 0 | $0 | 41,427 | $113,924 | 48,370 | $19,251 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-05-02 | PLX | Option Ex | 166,848 | 1.81 | 302,161 |
| 2012-05-02 | PLX | Sale | 166,848 | 7.13 | 1,189,626 |
| 2010-10-06 | PLX | Sale | 15,000 | 9.29 | 139,350 |
| 2010-10-05 | PLX | Sale | 20,000 | 9.08 | 181,600 |
| 2010-10-06 | PLX | Option Ex | 70,000 | .97 | 68,040 |
| 2010-10-04 | PLX | Sale | 35,000 | 9.02 | 315,700 |
| 2010-09-03 | PLX | Sale | 27,500 | 8.00 | 220,000 |
| 2010-09-07 | PLX | Option Ex | 50,000 | .69 | 34,300 |
| 2010-09-07 | PLX | Sale | 22,500 | 8.16 | 183,600 |
| 2009-10-16 | PLX | Sale | 23,680 | 9.39 | 222,355 |
| 2009-10-19 | PLX | Option Ex | 93,954 | .40 | 37,487 |
| 2009-10-19 | PLX | Sale | 38,320 | 9.43 | 361,357 |
| 2009-10-15 | PLX | Sale | 28,000 | 9.39 | 262,920 |
| 2009-07-07 | PLX | Sale | 11,000 | 4.95 | 54,450 |
| 2009-07-06 | PLX | Sale | 44,000 | 5.13 | 225,720 |
| 2009-07-07 | PLX | Option Ex | 59,822 | .40 | 23,868 |
| 2009-05-18 | PLX | Sale | 40,000 | 4.00 | 160,000 |
| 2009-05-18 | PLX | Option Ex | 44,707 | .40 | 17,838 |
| 2008-05-11 | PLX | Option Ex | 48,370 | .40 | 19,251 |
| 2008-05-12 | PLX | Sale | 41,427 | 2.75 | 113,924 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Almon Einat Brill (VP, Product Developm of Protalix Biotherapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.